In conclusion, this study reveals extensive synthetic lethal genetic interactions with EXO1 in human cells, which defines a framework for EXO1-based targeting of cancers with deficiencies in DDR pathways for which current therapeutic approaches are not sufficiently effective. Here, EXO1 is linked to cancer.